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Abstract
Background: In the era of intensity-modulated radiotherapy (IMRT), the efficacy of additional neoadjuvant
chemotherapy (NACT) to concurrent chemoradiotherapy (CCRT) in locoregionally advanced nasopharyngeal
carcinoma (NPC) is currently being investigated in ongoing trials. Overall survival (OS) is the gold standard
endpoint in NPC trials. We performed this analysis to identify surrogate endpoints for OS, which could shorten
follow-up duration and speed up assessment of treatment effects.
Methods: We retrospectively analysed 208 matched-pair patients with locoregionally advanced NPC receiving
NACT+CCRT or CCRT. Progression-free survival (PFS), failure-free survival (FFS), distant failure-free survival (D-FFS)
and locoregional failure-free survival (LR-FFS) at 2 and 3 years were assessed as surrogates for 5-year OS according
to Prentice’s criteria. The strength of the associations were assessed using Spearman’s rank correlation coefficient.
Results: No significant differences were observed between treatment arms for any surrogate endpoint at 2 years,
which rejected Prentice’s second criterion. In contrast, 3-year LR-FFS, PFS, FFS and D-FFS were consistent with all
four of Prentice’s criteria; the rank correlation coefficient (0.730) between 3-year PFS and 5-year OS was highest.
Conclusions: 3-year PFS, FFS and D-FFS could be valid surrogate endpoints for 5-year OS; 3-year PFS may be the
most accurate.
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Background
Nasopharyngeal carcinoma (NPC) is an epithelial malig-
nancy commonly observed in southern China, where the
incidence ranges from 15 to 50 per 100,000 [1]. Radio-
therapy (RT) is the mainstay treatment modality for
non-disseminated NPC. Although locoregional control
has improved as a result of the advent of intensity-
modulated radiation therapy (IMRT), the prognosis for
patients with locoregionally advanced NPC still remains
poor due to a high incidence of distant metastasis [2, 3].
As NPC is also relatively chemosensitive, numerous
studies have been conducted to evaluate the efficacy of
combining chemotherapy and RT in locoregionally
advanced NPC. Concurrent chemoradiotherapy (CCRT)
with or without adjuvant chemotherapy (AC) has been
demonstrated to be most efficacious, and is now recom-
mended as a standard treatment for patients with locore-
gionally advanced NPC [4, 5]. A meta-analysis indicated
that additional neoadjuvant chemotherapy (NACT) could
effectively enhance overall survival (OS) and reduce the
rate of distant metastasis [6]; however, in the IMRT era,
the addition of NACT to CCRT may provide better dis-
tant control and may be the most promising strategy [7].
To the best of our knowledge, only two phase II trials
[8, 9] comparing NACT+CCRT with CCRT and one
phase III trial [10] comparing NACT+CCRT with CCRT
+AC have been published so far. However, the phase II
trial by Hui et al. [8] reported an improvement in OS
with the addition of NACT, while the phase II trial by
Fountzilas et al. [9] failed to observe any significant
improvement in survival. Only the preliminary results of
the phase III trial by Lee et al. [10] have been reported,
with no significant differences in OS and progression-
free survival (PFS) between arms. The long-term results
of phase III trials are awaited to confirm the efficacy of
NACT+CCRT in NPC; we are currently conducting two
phase III trials (NCT01245959, NCT01872962).
In NPC trials, 5-year OS is commonly used to evaluate
the long-term benefits of a treatment. However, a large
sample size and a long follow-up period are required to
detect statistically significant differences in OS; non-
cancer deaths can also impact the measurement of OS.
Establishment of valid surrogate endpoints for OS could
shorten the duration of a trial, and thus help to assess
the results earlier and accelerate the discovery of more
effective therapeutic regimens. A set of statistical re-
quirements, known as Prentice’s four criteria, must be
met to validate surrogate endpoints [11]. In trials of
NPC, the potential surrogate endpoints for OS include
PFS, failure-free survival (FFS), distant failure-free sur-
vival (D-FFS) and locoregional failure-free survival (LR-
FFS). No study has yet assessed whether these endpoints
measured at an early time-point (e.g., 2 or 3 years) are
useful surrogates for 5-year OS in patients with
locoregionally advanced NPC receiving NACT+CCRT
versus CCRT alone. Therefore, we performed this ana-
lysis to evaluate whether 2- and 3-year PFS, FFS, D-FFS
or LR-FFS could be used as surrogate endpoints accord-
ing to Prentice’s criteria. The cisplatin-fluorouracil (PF)
regimen was adopted for additional NACT in the pa-
tients in this analysis, as this combination is commonly
used in the neoadjuvant phase at our centre and was
adopted in the phase III by Lee et al. [10]. The most re-
cent staging system (7th Union for International Cancer
Control/American Joint Committee On Cancer [UICC/




Between January 2003 and December 2007, all 749 patients
with newly-diagnosed, biopsy-proven, non-metastatic NPC
treated using IMRT at Sun Yat-Sen University Cancer Cen-
ter were retrospectively reviewed. Exclusion criteria were
as follows: (1) patients aged < 18 or > 70 years (n = 24); (2)
patients without locoregionally advanced NPC (stage III–
IV according to the 7th UICC/AJCC staging system; n =
253); (3) patients treated without CCRT, and patients
treated with AC (n = 124). An additional 64 patients who
did not receive the PF regimen as NACT or whose
chemotherapy regimen information was incomplete were
excluded. In the remaining 284 patients with locoregion-
ally advanced NPC who were treated with NACT+CCRT
or CCRT alone, we performed one-to-one pair matching
[12] between the patients receiving each therapeutic regi-
men based on the randomization pairing principle for
matched-pair analysis. Matching was performed according
to age, gender, T category, and N category. Finally, a total
of 208 matched-pair patients were analyzed in this study.
The clinical features of these patients are shown in
Table 1.
All patients completed a pretreatment evaluation in-
cluding a complete patient history, physical examination,
haematology and biochemistry profiles, magnetic reson-
ance imaging (MRI) of the neck and nasopharynx, chest
radiography, and abdominal ultrasonography; positron
emission tomography–computed topography (PET–CT)
was performed on 53/208 patients (25.5 %). All patients
were restaged according to the 7th UICC/AJCC staging
system [13]. All medical records and imaging studies
were reviewed to minimize heterogeneity in restaging.
Two radiologists specializing in head and neck cancer
evaluated the scans separately, and disagreements were
resolved by consensus. This study was approved by the
ethics committee of Sun Yat-Sen University Cancer Cen-
ter. As this was a retrospective analysis of routine data,
we were granted a waiver of written consent, and verbal
consent was obtained from the patients.
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Treatment and follow-up
All patients underwent radical radiotherapy and received
a planned total dose of 68–76 Gy (2–2.27 Gy per frac-
tions, five fractions per week). The nasopharyngeal and
upper neck tumour volumes were treated using IMRT
for the entire treatment course. A conventional anterior
or anteroposterior opposing cervical technique was used
for the lower neck. Further details of the radiotherapy
techniques used at our centre have been reported
previously [3]. All patients received cisplatin-based con-
current chemotherapy. Concurrent chemotherapy was
initiated on the first day of RT with cisplatin either every
three weeks or weekly (based on the opinion of the indi-
vidual oncologists). No significant differences in long-
term survival outcomes and acute toxicity were found
between concurrent cisplatin administered weekly or
every three weeks [14]. The compliance of concurrent
cisplatin was good; over 90 % patients received at least
five weeks of concurrent cisplatin when administered
weekly, or received at least two cycles of of concurrent
cisplatin when administered every three weeks. Add-
itionally, 44/208 (21.1 %) patients received fluorouracil
in the concurrent phase, and 104 patients received add-
itional neoadjuvant chemotherapy based on the PF
regimen. Reasons for deviation from institutional guide-
lines included refusal by individual patients or age or
organ dysfunction suggestive of intolerance to chemo-
therapy. When possible, salvage treatments such as in-
tracavitary brachytherapy, surgery and chemotherapy
were provided in the event of documented relapse or
persistent disease.
The median follow-up was 76 months (range, 6–123
months). Follow-up duration was calculated from the
first day of therapy to the day of death or last examin-
ation. Patients were examined at least every 3 months
during the first 2 years, and 6 months thereafter until
death. Endoscopy, CT or MRI scans of the head and
neck were performed every 3 months during the first
year and annually during years 2–5. Patients with re-
sidual or recurrent local disease underwent biopsy to
confirm malignancy. Additional tests were ordered when
indicated to evaluate for local or distant failure.
Study endpoints
The standard endpoint was 5-year OS, which was calcu-
lated from the first day of treatment to death from any
cause. The following potential surrogate endpoints mea-
sured at 2 and 3 years were estimated: PFS (calculated
from first day of treatment to failure or death from any
cause), FFS (calculated from first day of treatment to
first failure at any site), D-FFS and LR-FFS (calculated
from the first day of treatment to the first distant and
locoregional failure, respectively). All events taking place
after the 2 or 3-year time-points were censored.
Statistical analysis
The surrogate endpoints were evaluated using Prentice’s
four criteria [11]. A surrogate for a true endpoint should
validate a test of the null hypothesis that no correlation
exists between the treatment and the true response.
Prentice’s four criteria are as follows: (1) treatment is a
significant prognostic factor for the true endpoint (e.g.,
5-year OS); (2) treatment is a significant prognostic fac-
tor for the surrogate endpoint (e.g., 2- and 3-year PFS,
FFS, D-FFS or LR-FFS ); (3) the surrogate endpoint is a
significant prognostic factor for the true endpoint; and
(4) the full effect of the treatment on the true endpoint
should be explained by the surrogate endpoint. The ac-
tuarial rates for the true and surrogate endpoints were
estimated using the Kaplan–Meier method; survival
curves were compared using the log-rank test [15]. The
adjusted Cox proportional hazard models with backward
elimination were used to calculate the hazard ratio (HR)
between treatments with respect to each outcome [16].
The following parameters were included in the model as
covariates: age (>50 vs. ≤ 50 years), gender (male vs. fe-
male), T category (T3–4 vs. T1–2), N category (N1–3 vs.
N0), treatment arm (NACT+CCRT vs. CCRT) for
Table 1 Clinical features of the 208 matched-pair patients with
nasopharyngeal carcinoma
Characteristic NACT+CCRT group CCRT group
(n = 104, %) (n = 104, %)
Age, years
≤ 50 86 (82.7) 86 (82.7)
> 50 18 (17.3) 18 (17.3)
Gender
Male 82 (78.8) 82 (78.8)
Female 22 (21.2) 22 (21.2)
T category a
T1 7 (6.7) 7 (6.7)
T2 5 (4.8) 5 (4.8)
T3 63 (60.6) 63 (60.6)
T4 29 (27.9) 29 (27.9)
N category a
N0 13 (12.5) 13 (12.5)
N1 61 (58.7) 61 (58.7)
N2 22 (21.2) 22 (21.2)
N3 8 (7.7) 8 (7.7)
Stage b
III 68 (65.4) 68 (65.4)
IVA–IVB 36 (34.6) 36 (34.6)
Abbreviations: CCRT concurrent chemoradiotherapy; NACT neoadjuvant
chemotherapy
aAccording to the American Joint Committee on Cancer, 7th edition
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Prentice’s criterion one, two and four, and surrogate
endpoints (with vs. without events ≤ 2/3 years) for Pren-
tice’s criterion three. Additionally, the Spearman’s rank
correlation coefficients (ρ) for the distribution of the
candidate surrogates and 5-year OS at the individual
level were calculated to assess the strength of the associ-
ations, using a bivariate survival model [17]; ρ2 reflects
the amount of variation explained by the surrogate. SPSS
19.0 software (IBM, Armonk, NY, USA) was used for all
analysis.
Results
Among the 208 matched-pair patients, a total of 58
(27.9 %) patients experienced treatment failure and 56
(26.9 %) patients died during the follow-up period. As
expected, locoregional control was good with the adoption
of IMRT, and only 21 (10.1 %) patients developed locore-
gional failure. Most failures occurred at distant sites, with
48 (23.1 %) patients developing distant metastasis.
Evaluation of surrogate endpoints
Prentice’s criterion one
The 5-year OS rate was 72 % in the CCRT group and
84 % in the NACT+CCRT group, with a marginally sig-
nificant difference (Plog-rank = 0.050; Fig. 1). The adjusted
HR for NACT+CCRT versus CCRT was 0.542 (95 % CI,
0.298–0.987; PCox = 0.045). Therefore, Prentice’s first cri-
terion, that the treatment is a significant prognostic fac-
tor for the true endpoint, 5-year OS, was met.
Prentice’s criterion two
Though the 2-year PFS and D-FFS rates of the patients in
the NACT+CCRT group tended to be better than those of
the CCRT group, no statistically significant differences with
respect to any surrogate endpoint measured at 2 years were
observed between treatments (Table 2). In contrast,
compared to patients in the CCRT group, those in the
NACT+CCRT group had significantly better 3-year PFS
(HR = 0.561, 95 % CI 0.317–0.994; PCox = 0.048), 3-year FFS
(HR = 0.527, 95 % CI 0.285–0.975; PCox = 0.041) and 3-year
D-FFS (HR = 0.458, 95 % CI 0.230–0.912; PCox = 0.026;
Table 2). Treatment was not significantly prognostic for 3-
year LR-FFS. Therefore, Prentice’s second criterion that the
treatment is a significant prognostic factor for the surrogate
endpoint was only met for 3-year PFS, FFS and D-FFS.
Prentice’s criteria three and four
Table 3 summarizes the testing of the surrogates for 5-
year OS according to Prentice’s criteria three and four.
As treatment was not prognostic for all surrogates at
2 years and locoregional failure at 3 years, these end-
points were not included in these tests. When measured
at 3 years, PFS, FSS and D-FSS all had a significant
impact on 5-year OS (all PCox < 0.001; Table 3).
To assess Prentice’s criterion four, first we tested the
hypothesis that 5-year OS was independent of treatment
if patients had failure or death due to any cause, failure
at any site, or distant metastasis ≤ 3 years. Then we
tested the second hypothesis that 5-year OS was inde-
pendent of treatment if none of the abovementioned
events occurred ≤ 3 years. The treatment effect of NACT
+CCRT versus CCRT on 5-year OS was not statistically
significant for either hypothesis (all PCox > 0.10; Table 3).
These findings suggest that the full effect of treatment
on 5-year OS may be explained by the potential surro-
gate endpoints, independent of treatment, and so Pren-
tice’s fourth criterion was also satisfied.
Therefore Prentice’s third criterion, that the surrogate
endpoint is significantly prognostic for the true endpoint,
and Prentice’s fourth criterion, that the full effect of the
Fig. 1 Survival curves for overall survival (OS), and potential surrogate endpoints. Kaplan–Meier survival curves of (a) OS and progression–free
survival (PFS), (b) OS and failure–free survival (FFS), and (c) OS and distant failure–free survival (D-FFS) in the neoadjuvant chemotherapy followed
by concurrent chemoradiotherapy (NACT+CCRT) group and CCRT alone group. Survival curves were truncated at 5 years. The numbers of
patients at risk in each group are provided below the graph
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treatment on 5-year OS could be explained by the surrogate
endpoint, were both met for 3-year PFS, FFS and D-FFS.
Strength of the associations between surrogate endpoints
and 5-year OS
The strength of the associations between the surrogate
endpoints and 5-year OS were assessed using the Spear-
man’s rank correlation coefficient. The association
between 3-year PFS and 5-year OS was relatively strong
(ρ2 = 0.730), while the rank correlation coefficients were
0.661 for 3-year D-FFS and 5-year OS and 0.632 for 3-
year D-FFS and 5-year OS.
Discussion
During the last decade, the advanced therapeutic strat-
egies introduced in the IMRT era have been widely
Table 2 Survival outcomes for the surrogate endpoints at 2 and 3 years
Surrogate
endpoint
Events Survival rates a





(n = 104, %) (n = 104, %) No. (%)
At 2 years
PFS 15 (14.4) 25 (24.0) 40 (29.2) 87 76 0.078
FFS 14 (13.5) 22 (21.2) 36 (27.3) 87 79 0.134
D-FFS 12 (11.5) 21 (20.2) 33 (15.9) 88 80 0.092
LR-FFS 3 (2.9) 6 (5.8) 9 (4.3) 98 94 0.284
At 3 years
PFS 19 (18.3) 31 (29.8) 50 (24.0) 83 72 0.049
FFS 16 (15.4) 28 (26.9) 44 (21.2) 85 75 0.040
D-FFS 12 (11.5) 25 (24.0) 37 (17.8) 88 77 0.022
LR-FFS 5 (4.8) 9 (8.7) 14 (6.7) 95 92 0.235
Abbreviations: CCRT concurrent chemoradiotherapy; D-FFS distant failure-free survival; FFS failure-free survival; LR-FFS locoregional failure-free survival;
NACT neoadjuvant chemotherapy; PFS progression-free survival
aThe survival rates for the surrogate endpoints were estimated using the Kaplan-Meier method
*P-values were calculated using the log-rank test
Table 3 Testing of Prentice’s criteria three and four for the potential surrogate endpoints for 5-year OSa
Prentice’s criteria HR (95 % CI)c P-value*
Prentice’s criterion three: Is the surrogate endpoint prognostic for 5-year OS?
Failure or death from any cause≤ 3 yearsb 39.0 (16.5–92.3) <0.001
Failure at any site ≤ 3 yearsb 14.9 (7.9–28.1) <0.001
Distant metastasis≤ 3 yearsb 18.1 (9.7–33.8) <0.001
Prentice’s criterion four: Is treatment still prognostic for 5-year OS in
patients stratified by the surrogate?
Patients with failure or death from any cause≤ 3 years
Yes NS >0.10
No NS >0.10
Patients with failure at any site≤ 3 years
Yes NS >0.10
No NS >0.10
Patients with distant metastasis ≤ 3 years
Yes NS >0.10
No NS >0.10
Abbreviations: CI confidence interval; HR hazard ratio; NS not significant; OS overall survival
aAs treatment was not prognostic for any surrogates measured at 2 years and locoregional failure at 3 years, Prentice’s criterion three and four were not tested for
these endpoints
bThe reference groups were no events ≤ 3 years
cHazard ratios were adjusted for the following parameters using a Cox proportional hazards model by backward elimination: age (>50 vs. ≤ 50 years), gender
(male vs. female), T category (T3–4 vs. T1–2), N category (N1–3 vs. N0), surrogates (with vs. without events ≤ 3 years) for Prentice’s criterion three only, and
treatment arm (neoadjuvant chemotherapy + concurrent chemoradiotherapy vs. concurrent chemoradiotherapy) for Prentice’s criterion four only
*P-values were calculated using the adjusted Cox proportional hazards model
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adopted and systematic treatments such as the addition of
NACT has been an area of intense research. Currently,
two phase III trials are being undertaken by our group to
confirm the efficacy of NACT+CCRT in locoregionally ad-
vanced NPC (NCT01245959, NCT01872962). The prelim-
inary results of NCT01245959 are yet to be reported.
Identification of a valid surrogate endpoint for OS could
help to assess long-term survival by observing the surrogate
endpoint at earlier time-points. In this retrospective study,
we applied the surrogacy criteria devised by Prentice to as-
sess which endpoints could represent useful surrogates for
5-year OS in patients with locoregionally advanced NPC re-
ceiving additional NACT. 3-year PFS, FFS and D-FFS were
consistent all four of Prentice’s criteria and were validated
as surrogate endpoints for 5-year OS, while 3-year LR-FFS
and all endpoints measured at 2 years were not confirmed
as surrogates. Moreover, compared to FFS and D-FFS,
PFS measured at 3 years had the strongest association
with 5-year OS (ρ = 0.730). Thus, 3-year PFS, FFS and D-
FFS could enable the early assessment of treatment effects
on long-term survival using preliminary trial results, with
3-year PFS likely to provide the most accurate prediction
of 5-year OS.
With the widespread use of IMRT, the prognosis of
patients with NPC has greatly improved, with fewer
treatment failures at locoregional sites now occurring
[18]. Use of surrogate endpoints measured too early may
produce fewer events, which would increase the diffi-
cultly of reaching statistical significance and result in less
precise prediction of the true endpoint. In this analysis,
all endpoints measured at 2 years did not comply with
Prentice’s second criterion: no significant differences
were observed between treatment groups. During the
validation process of surrogate endpoints, the level of
significance of treatment effect should be taken into
account [19]; endpoints with non significant treatment
effects could not serve as good surrogates. However, 2-
year PFS and D-FFS trended towards significance, which
suggests that future trials recruiting larger numbers of
patients, despite the costing more, would observe a
higher number of events that may enable 2-year PFS and
D-FFS and even FFS, to meet this criterion. Extending
the follow-up duration to 3 years, PFS, FFS and D-FFS
were validated as surrogate endpoints for 5-year OS.
However, due to the excellent locoregional control by
IMRT, NACT+CCRT over CCRT alone did not lead to
superior LR-FFS, and Prentice’s second criteria was not
met for LR-FFS. As the definition of PFS included failure
at any site as well as death, which overlaps with the
definition of OS, the rank correlation coefficient between
3-year PFS and 5-year OS was relatively high. As it was
biased by the insignificant improvement in locoregional
control provided by NACT, the predictive ability of 3-
year FFS was weakened, and FFS and 5-year OS had a
smaller correlation coefficient than 3-year D-FFS and 5-
year OS. Thus, PFS, FFS and D-FFS measured at 3 years
could all serve as surrogate endpoints for long-term OS;
3-year PFS may be the most appropriate and accurate.
Generally, in a trial with the same number of patients
and duration of follow-up, the number of events will be
higher or equal for surrogate endpoints (especially PFS)
than for OS. Therefore, a valid surrogate endpoint could
increase the statistical power to observe significant
differences between treatment groups, allowing smaller
randomized clinical trials to be carried out and shorten-
ing the follow-up period. Use of surrogate endpoints
may also permit earlier reporting of a trial and enhance
interpretation of the preliminary results, thereby acceler-
ating the development of new treatment strategies (e.g.,
the addition of NACT to CCRT). Furthermore, when as-
sessment of OS may be contaminated by administration
of salvage therapies after treatment failures and non-
cancer deaths, surrogate endpoints could reduce the risk
of abandoning potentially effective new therapeutic
regimens.
A limitation of this analysis is that it is a retrospective
study of patients from a single centre. The retrospective
nature of the analysis may have confounded the results
to a certain extent; using data from randomized trials
performed at different centres could make the results
more persuasive. However, no long-term results of phase
III trials comparing NACT+CCRT with CCRT have yet
been reported. In order to reduce bias and reflect typical
trial conditions in this study, we applied the newest
staging system, included patients with long-term follow-
up and performed matched-paired analysis. Our analysis
may provide a reference for future trials that are yet to
be reported. Another limitation of this study is that the
results should be interpreted with caution when applying
statistical methods such as Prentice’s criteria to establish
surrogate endpoints [20]. As the fourth criterion is for-
mulated in terms of an equivalence setting, which is
relatively difficult to meet, not rejecting this criterion is
not necessarily definite evidence that the criterion holds
[21]. However, PFS, FFS and D-FFS measured at 3 years
did satisfy all four criteria, confirming their validity as
surrogate endpoints for 5-year OS. Third, we should
note that the Prentice’s criteria only ensures that the
treatment effect of the true endpoint implies the treat-
ment effect also on the surrogates; it does not ensure
the converse [22]. It means that a signicant treatment
effect on 3-year PFS, FFS or D-FFS can not promise a
significant treatment effect on the 5-year OS; uncertainty
exists in using surrogate.
It is important to keep in mind that extrapolation of a
surrogate endpoint validated for a specific therapeutic
regimen to other regimens with totally different mecha-
nisms of action may not be reliable. In this study, NACT
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based on the PF regimen was investigated; this regimen
was also adopted for NACT in a phase III trial that com-
pared NACT+CCRT with CCRT+AC in locoregionally
advanced NPC and recently published preliminary re-
sults [10]. The two ongoing phase III trials by our group
are designed to evaluate the taxane-PF regimen and
gemcitabine-cisplatin regimen for NACT, respectively.
Though application of the surrogate endpoints identified
in this study may be suitable for these traditional che-
motherapeutic agents, surrogate endpoints should be
directly verified in trials evaluating targeted or immuno-
logical therapies, which have totally different pharmaco-
dynamic profiles.
In conclusion, this analysis identified 3-year PFS, FFS and
D-FFS as valid surrogate endpoints for 5-year OS in pa-
tients with locoregionally advanced NPC receiving NACT
+CCRT versus CCRT alone. 3-year PFS may be more useful
for early assessment of treatment effects. Long-term follow-
up is still required in future trials to confirm the efficacy of
the treatments and monitor unexpected late adverse effects.
Future trials should continue to be designed with OS the
main end-point in conjunction with potential surrogate
endpoints.
Conclusions
We performed a retrospective study to eatimate whether
2- and 3-year PFS, FFS, D-FFS, and LR-FFS could be used
as surrogate endpoints for 5-year OS in patients with
locoregionally advanced NPC receiving NACT+CCRT
versus CCRT alone. We demonstrated that 3-year PFS,
FFS, and D-FFS could be valid surrogates, while 3-year
PFS may be the most accurate. Establishment of these
surrogate endpoints for OS could shorten the duration of
a trial, thus help us assess the results earlier, and accelerate
the finding of effective therapeutic regimens.
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